Logica Platform (Logica-A, Logica-B, Logica-C)

Logica® is an integrated, AI-driven drug discovery platform developed through the combined expertise of Charles River and Valo Health. Designed for pharmaceutical and biotech organizations seeking to advance small molecule programs, Logica is not a standalone AI point solution but a comprehensive, end-to-end partner that aligns its processes to each client's specific drug discovery objectives. With over 100 candidates delivered to clients across numerous therapeutic areas and target classes, Logica offers a proven track record backed by deep experimental and computational capabilities.

The platform is structured around three modular solutions — Logica-A (in vitro biology), Logica-B (pharmacokinetics and pharmacodynamics), and Logica-C (efficacy and therapeutic window) — which can be engaged individually or in any combination to meet the needs of a given program.

Logica-A: In Vitro Biology

• Access to a virtual compound library of over 30 billion compounds, a high-throughput screening (HTS) library of over 1 million members, and DNA-encoded compound library (DEL) data covering over 13 billion members
• Expert knowledge and data science applied to large, wide-ranging datasets to systematically sort and characterize compound activity and quality
• AI/ML-based models paired with in vitro biology assays to characterize the most promising compounds
• Comprehensive target assays, selectivity panels, and initial characterization to identify an advanceable lead series

Logica-B: Pharmacokinetics and Pharmacodynamics

• Comprehensive ADME profiling to understand compound behavior in biological systems
• In vivo pharmacokinetics assessment across relevant species
• Bioavailability and distribution analysis
• Metabolic pathway characterization
• Translational PK/PD support during lead optimization and into candidate selection
• Integration of PK/PD datasets with predictive modeling for data-driven decision-making
• Optimization recommendations for improved drug-like properties
• Risk assessment to support advancement decisions

Logica-C: Efficacy and Therapeutic Window

• Pharmacodynamic (PD) studies to understand target engagement in vivo and inform dosing for efficacy studies
• Establishment of therapeutic window through integrated efficacy models, PK/PD analysis, and non-GLP rodent toxicology
• Clear go/no-go recommendations based on therapeutic index analysis

Key Deliverable Outcomes: Certainty, Quality, and Advanceability

• Certainty: Clear characterization of in vitro biology profiles; PK/PD and exposure–response modeling to predict dose, schedule, and therapeutic window; demonstrated in vivo target engagement signals
• Quality: Comprehensive assessment using validated assays and proven methodologies; validated bioanalytical methods and standardized ADME/PK workflows for reproducible, audit-ready data; de-risked molecules confirmed to modulate the target in vivo
• Advanceability: Data packages supporting informed advancement decisions; data-driven optimization recommendations; clear therapeutic index data supporting progression to formal development

Therapeutic Areas and Target Classes

• Therapeutic areas covered include CNS, oncology, fibrosis, respiratory, anti-infective, and others
• Target classes include kinases, phenotypic targets, ion channels, proteases, enzymes, RNA targets, transcription factors, membrane receptors, GPCRs, and others

Logica's defining strength lies in the native integration of industry-leading AI-driven modeling with extensive experimental capabilities, enabling a well-guided and efficient journey from target identification through to preclinical development. Clients benefit from true flexibility, with the ability to engage at any single phase or across multiple phases depending on their program requirements.